Edward Smith - Conatus Pharmaceuticals Insider

CNAT -- USA Stock  

USD 5.37  0.38  7.62%

Senior Vice President - Regulatory Affairs and Quality Assurance

Dr. Edward F. Smith III., Ph.D. is Senior Vice President Regulatory Affairs and Quality Assurance of the company. He was Vice President, Regulatory Affairs and Drug Safety at Zogenix, Inc., since October 2008, which he joined as Senior Director, Regulatory Affairs in April 2007. Before joining Zogenix, he served as Senior Director, Regulatory Affairs at Connetics Corporationration from 2006 to 2007 Director, Regulatory Affairs at Nektar Therapeutics from 2004 to 2006 Director, Corporationrationrate Regulatory Affairs at Valeant Pharmaceuticals from 2001 to 2004 and Vice President, Regulatory Affairs and Research Development at Radiance Medical Systems, Inc., from 1999 to 2001. He previously held research and development positions at Mallinckrodt Inc. from 1992 to 1999, at SmithKline Beecham Pharmaceuticals from 1986 to 1992, and at CibaGeigy from 1984 to 1985. Dr.160Smith held postdoctoral fellowships at the Institute of Pharmacology at the University of Koln in Germany, and the Medical University of South Carolina
  President Since 2016  MBA    
858-376-2600  http://www.conatuspharma.com
#160;Smith received a B.S. in biology from Montana State University, a Ph.D. in physiology from Thomas Jefferson University, and an M.B.A. from Washington University. He also holds a Regulatory Affairs Certification.

Edward Smith Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (14.76) % which means that it has lost $14.76 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (87.78) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 13.34 M in liabilities with Debt to Equity (D/E) ratio of 57.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals has Current Ratio of 2.36 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. The company was founded in 2005 and is headquartered in San Diego, California. Conatus Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 33 people.Conatus Pharmaceuticals (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 33 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Conatus Pharmaceuticals Leadership Team

Edward Smith, President, MBA
Michelle Vandertie, Executive
Dan Kisner, Director
James Scopa, Director
Steven Mento, CEO
Daniel Kisner, Director
Preston Klassen, Director
David Hale, Chairman
Harold Wart, Director, Ph.D
William LaRue, Director, MBA
Alfred Spada, Founder, Ph.D
Charles Cashion, President, MBA
Daniel Ripley, President, MBA
Keith Marshall, President, MBA
Louis Lacasse, Director, MBA
Shahzad Malik, Director
David Hagerty, President

Stock Performance Indicators

Current Sentiment - CNAT

Conatus Pharmaceuticals Investor Sentiment
Most of Macroaxis users are currently bullish on Conatus Pharmaceuticals. What is your opinion about investing in Conatus Pharmaceuticals? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Conatus Pharmaceuticals and NantKwest. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Portfolio Quick Import module to import or update all your transactions via one easy-to-use interface.